For decades, researchers and biotech companies have struggled to develop diagnostic tools and treatments for Alzheimer’s, a disorder that causes loss of memory and other mental functions and affects nearly 6.5 million Americans.  Now they’re slowly making progress. A drug called lecanemab was approved this year that can slow the disease’s progression, sparking renewed optimism […]